A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer.

Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, Bao L, Sun HC, Macarulla T, Xie F, Metges JP, Ying J, Bridgewater J, Lee MA, Tejani MA, Chen EY, Kim DU, Wasan H, Ducreux M, Bao Y, Lindsey S, Bachini M, Morement H, Boyken L, Ma J, Garfin P, Pant S, HERIZON-BTC-01 study group

Open source

DOI: 10.1080/14796694.2024.2368952
Published: 2024
Container: Future oncology (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2024.2368952,
  title = {A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer.},
  author = {Harding JJ and Fan J and Oh DY and Choi HJ and Kim JW and Chang HM and Bao L and Sun HC and Macarulla T and Xie F and Metges JP and Ying J and Bridgewater J and Lee MA and Tejani MA and Chen EY and Kim DU and Wasan H and Ducreux M and Bao Y and Lindsey S and Bachini M and Morement H and Boyken L and Ma J and Garfin P and Pant S and HERIZON-BTC-01 study group},
  year = {2024},
  journal = {Future oncology (London, England)},
  doi = {10.1080/14796694.2024.2368952},
  url = {https://doi.org/10.1080/14796694.2024.2368952}
}

RIS

TY  - JOUR
TI  - A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer.
AU  - Harding JJ
AU  - Fan J
AU  - Oh DY
AU  - Choi HJ
AU  - Kim JW
AU  - Chang HM
AU  - Bao L
AU  - Sun HC
AU  - Macarulla T
AU  - Xie F
AU  - Metges JP
AU  - Ying J
AU  - Bridgewater J
AU  - Lee MA
AU  - Tejani MA
AU  - Chen EY
AU  - Kim DU
AU  - Wasan H
AU  - Ducreux M
AU  - Bao Y
AU  - Lindsey S
AU  - Bachini M
AU  - Morement H
AU  - Boyken L
AU  - Ma J
AU  - Garfin P
AU  - Pant S
AU  - HERIZON-BTC-01 study group
PY  - 2024
JO  - Future oncology (London, England)
DO  - 10.1080/14796694.2024.2368952
UR  - https://doi.org/10.1080/14796694.2024.2368952
ER  -

APA

JJ, H., J, F., DY, O., HJ, C., JW, K., HM, C., L, B., HC, S., T, M., F, X., JP, M., J, Y., J, B., MA, L., MA, T., EY, C., DU, K., H, W., M, D., Y, B., S, L., M, B., H, M., L, B., J, M., P, G., S, P., & group, H. S. (2024). A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer.. Future oncology (London, England). https://doi.org/10.1080/14796694.2024.2368952

Source records

pubmed · retrieved 2026-09-26T19:48:46.860Z